Vopratelimab

• Description:

  Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS) . Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response[1].

• Product Name Alternative:

  JTX 2011; 37A10

• UNSPSC:

  12352203

• Target:

  Others

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/vopratelimab.html

• Purity:

  99.98

• Solubility:

  10 mM in DMSO

• Smiles:

  [Vopratelimab]

• Molecular Weight:

  (145.8 kDa)

• References & Citations:

  [1]Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15 (9) :e0239595.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2

• CAS Number:

  [2039148-04-2]